KLF5 and breast carcinoma: Besides TNBC cells, FZU-00,003 also showed strong survival inhibition effects in other subtypes of breast cancer (Fig 1C), indicating FZU-00,003 may also be effective in treating luminal and HER2 positive breast cancers through other mechanisms since KLF5 is lowly expressed in these subtypes of breast cancer cells 18.